Geron to Present at Upcoming Investor Conferences

Geron (GERN) will participate in two upcoming investor conferences in New York in September 2026.

Rhea-AI Summary

Geron (GERN) will participate in two upcoming investor conferences in New York in September 2026.

The company will host a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 8:00 a.m. ET and at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 3:30 p.m. ET. Live and archived audio webcasts will be accessible via the Investor section of Geron’s website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:

• 2026 Cantor Global Healthcare Conference:
  Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY

• H.C. Wainwright 28th Annual Global Investment Conference:
  Fireside Chat on Tuesday, September 15, 2026, at 3:30 p.m. ET in New York, NY

Live and archived audio webcasts of the fireside chats will be available through the Investor section of Geron’s website at www.geron.com.

About Geron 
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

FAQ

When will Geron (GERN) present at the 2026 Cantor Global Healthcare Conference?

Geron is scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY.

When is Geron (GERN) presenting at the H.C. Wainwright 28th Annual Global Investment Conference?

Geron will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 3:30 p.m. ET in New York, NY.

How can investors listen to Geron’s September 2026 conference presentations?

Live and archived audio webcasts of Geron’s fireside chats at both September 2026 conferences will be available through the Investor section of the company’s website at www.geron.com.

Where will Geron’s September 2026 investor conference fireside chats take place?

Geron’s fireside chats for the 2026 Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference will both take place in New York, NY in September 2026.